Abstract

Background

Parkinson’s disease (PD) is a progressive neurodegenerative disorder. The major causative factors that progress the PD are age, genetic abnormalities, environmental factors and degeneration of dopamine neurons in substantia nigra. PD normally exerts a tonic inhibitory effect on striatal cholinergic interneurons. Anticholinergics act by normalizing the disequilibrium between striatal dopamine and acetylcholine-resulted reduction in tremors.

Objective

This study sought to evaluate the anti-Parkinson potential of dicyclomine in haloperidol (HAL)- and paraquat (PQT)-induced Parkinsonism models in mice.

Materials and methods

Sixty albino mice were divided into six groups (n = 10) for each model. Group I: received distilled water 1 mL/kg, Group II: diseased group received HAL (1 mg/kg) for consecutive 21 days and PQT (2 mg/kg) every three days for three weeks, Group III: treated with sinemet (20 mg/kg), Group IV–VI: received 40, 80 and 160 mg/kg dose of dicyclomine, respectively, for consecutive 21 days. The effect of treatments on spontaneous locomotor activity and motor co-ordination was evaluated by using open field, rotarod, actophotometer and light and dark box tests. Cataleptic behavior was estimated by the block method and triple horizontal bar apparatus. Biochemical markers of oxidative stress and levels of neurotransmitters were estimated.

Results

Findings from this study showed that dicyclomine at highest dose level of 160 mg/kg prevented HAL- and PQT-induced PD through enhancement of antioxidant defense system.

Conclusion

The study concluded that dicyclomine could be the potential drug in the management of Parkinsonism.

中文翻译：

---

双环胺抗帕金森活性的研究

摘要

背景

帕金森病 (PD) 是一种进行性神经退行性疾病。导致PD进展的主要致病因素是年龄、遗传异常、环境因素和黑质多巴胺神经元的退化。PD 通常对纹状体胆碱能中间神经元具有强直抑制作用。抗胆碱能药通过使纹状体多巴胺和乙酰胆碱导致的震颤减少之间的不平衡正常化而起作用。

客观的

本研究旨在评估双环胺在氟哌啶醇 (HAL) 和百草枯 (PQT) 诱导的小鼠帕金森病模型中的抗帕金森病潜力。

材料和方法

每个模型将 60 只白化小鼠分为六组 ( n  = 10)。第一组：接受蒸馏水 1 mL/kg，第二组：疾病组连续 21 天接受 HAL（1 mg/kg）和 PQT（2 mg/kg）每三天一次，连续三周，第三组：用 sinemet 治疗（ 20 mg/kg)，IV-VI 组：分别接受 40、80 和 160 mg/kg 剂量的双环胺，连续 21 天。通过使用开放场、旋转棒、光度计和明暗箱测试来评估治疗对自发运动活动和运动协调的影响。通过块法和三重水平杆装置估计僵直行为。估计了氧化应激的生化标志物和神经递质的水平。

结果

这项研究的结果表明，最高剂量 160 mg/kg 的双环胺通过增强抗氧化防御系统来预防 HAL 和 PQT 诱导的 PD。

结论

该研究得出结论，双环胺可能是治疗帕金森症的潜在药物。